Cancer Genetics Inc. (NASDAQ:CGIX) announced its earnings results on Thursday. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.05. The company earned $6.80 million during the quarter, compared to the consensus estimate of $6.93 million. Cancer Genetics had a negative return on equity of 72.29% and a negative net margin of 89.60%. The firm’s revenue for the quarter was up 70.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.56) earnings per share.

Shares of Cancer Genetics (NASDAQ:CGIX) opened at 1.35 on Thursday. The stock’s market capitalization is $21.76 million. The stock has a 50 day moving average price of $1.59 and a 200-day moving average price of $2.00. Cancer Genetics has a 1-year low of $1.10 and a 1-year high of $3.93.

Earnings History for Cancer Genetics (NASDAQ:CGIX)

In other Cancer Genetics news, Director John Pappajohn purchased 45,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The stock was purchased at an average cost of $2.29 per share, with a total value of $103,050.00. Following the purchase, the director now owns 2,287,109 shares of the company’s stock, valued at $5,237,479.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 25.40% of the company’s stock.

A hedge fund recently raised its stake in Cancer Genetics stock. Vanguard Group Inc. raised its stake in Cancer Genetics Inc. (NASDAQ:CGIX) by 3.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 326,966 shares of the company’s stock after buying an additional 10,328 shares during the period. Vanguard Group Inc. owned about 2.40% of Cancer Genetics worth $651,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.66% of the company’s stock.

Several equities research analysts recently weighed in on CGIX shares. Zacks Investment Research raised Cancer Genetics from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Thursday, July 28th. Rodman & Renshaw started coverage on Cancer Genetics in a research note on Monday, September 26th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, HC Wainwright started coverage on Cancer Genetics in a research note on Tuesday, September 27th. They issued a “buy” rating and a $6.00 price target on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $7.06.

About Cancer Genetics

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

5 Day Chart for NASDAQ:CGIX

Receive News & Stock Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related stocks with our FREE daily email newsletter.